International Stem Cell Corp. (ISCO) Prepares to Begin Clinical Study of Novel Parkinson’s Disease Treatment Option
Imagine a world where there is no donor organ shortage, victims of spinal cord injuries can walk and weakened hearts are successfully replaced; this is the future of regenerative medicine, as outlined by the National Institute of Health. To obtain the massive promises of this revolutionary treatment option, however, it is necessary to successfully overcome the barriers associated with immune response, which have, to this point, severely hampered the advancement of cell replacement therapies. International Stem Cell Corporation (OTCQB: ISCO), through the continued development of its groundbreaking parthenogenesis stem cell technology, is addressing this limitation, potentially unlocking the door to…